Director Shareholding (9700F)

TIDMISPH

RNS Number : 9700F

IS Pharma PLC

04 May 2011

04 May 2011

IS Pharma plc

('IS Pharma' or the 'Company')

Director Shareholding

IS Pharma plc (LSE: ISPH), the international speciality pharmaceutical company, announces that application has been made for the admission to trading on AIM of 44,386 new ordinary shares of 10p each in the capital of the Company ("Ordinary Shares") issued following the exercise today of options granted to John Gregory, Chairman, under IS Pharma's unapproved share option scheme. It is expected that these Ordinary Shares will be admitted to trading on 10 May 2011.

As a result of this option exercise, John Gregory holds an interest in 93,701 Ordinary Shares representing 0.18% of the Company's current issued share capital.

Following the exercise of these options IS Pharma has a total of 52,045,066 Ordinary Shares in issue at the date of this notice with each share carrying the right to one vote. There are no shares held in treasury. The total number of voting rights in the Company is therefore 52,045,066.

The above figure may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure and Transparency Rules.

- Ends -

For further information, call:

IS Pharma plc Tel: [phone]

John Gregory, Chairman

Tim Wright, Chief Executive Officer

Matthew Hall, Chief Financial Officer

Financial Dynamics Limited Tel: [phone]

Billy Clegg I Edward Westropp

finnCap Limited Tel: [phone]

Matthew Robinson

Ed Frisby

A copy of this announcement will be available on the website of IS Pharma at www.ispharma.plc.uk.

IS Pharma (International Speciality Pharmaceuticals) is a fast growing, profitable business which develops, acquires and commercialises late-stage pharmaceuticals and medical devices, focusing in critical care, oncology and neurology. Based in the UK, IS Pharma commercialises its portfolio in the UK directly and internationally through a strong network of distributors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSLLFVDELISIIL